PCA
SIOX

Private Capital Advisors’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Private Capital Advisors’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,013
Closed -$349K – 90
2022
Q3 		$349K Buy
+3,013
New +$1.03K 0.06% 64
2015
Q3 		– Sell
-2,125
Closed -$346K – 128
2015
Q2 		$346K Buy
+2,125
New +$360K 0.11% 118

Other funds holding SIOX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
TVWM
Tower View Wealth Management Shorewood, Wisconsin $195M AUM 29.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Private Capital Advisors's SIOX Position: Q4 2022 in Review

Private Capital Advisors sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2022, closing a stake of 3,013 shares — an estimated $349K sold.

Private Capital Advisors first reported a position in SIOX in Q2 2015 and held it in 2 quarters. The position peaked at $349K in Q3 2022. 37 funds tracked by Wall St. Rank hold SIOX as of Q4 2022.

  • Private Capital Advisors reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Private Capital Advisors sold 3,013 Sio Gene Therapies Inc. Common Stock shares in Q4 2022, an estimated $349K.
  • Private Capital Advisors first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2015 and held it in 2 quarters.
  • Private Capital Advisors's Sio Gene Therapies Inc. Common Stock position peaked at $349K in Q3 2022.
  • 37 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2022.

Based on Private Capital Advisors's 13F filing for Q4 2022, filed 8 Feb 2023.